Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients

High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroemer, Guido, Kepp, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632107/
https://www.ncbi.nlm.nih.gov/pubmed/34858731
http://dx.doi.org/10.1080/2162402X.2021.2005859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632107/
https://www.ncbi.nlm.nih.gov/pubmed/34858731
http://dx.doi.org/10.1080/2162402X.2021.2005859

Ejemplares similares